Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark

Søg

Menu

Close

Log indLog udLægemidlerTerapiområderPfizerConnectPfizerConnectArrangementerMaterialerEfteruddannelse
AboutAlopecia AreataLITFULO Mechanism of ActionSALT EvaluationEfficacyALLEGRO-2b/3 Study OverviewScalp Hair ResponsePatient-reported OutcomesEyebrow & Eyelash ResponseBefore & After ImagesSafetyALLEGRO-2b/3 Adverse ReactionsAdditional Safety ConsiderationsGetting StartedDosingScreening & MonitoringSetting Patient ExpectationsResourcesMaterialsVideos
Before & After Images

Scalp Hair Images

Tab Number 3

Tab Number 4

Tab Number 5

Clinical examples of development in SALT scores found in the pivotal trial.[1,2] 
  • All patients from the study had 50% or more scalp hair loss at baseline[1,2] 
  • There was no statistical significance between LITFULO 50 mg and placebo at Week 12[2] 
  • In 6 months,[1] 
    •   13.4% of patients achieved SALT ≤10with LITFULO 50 mg vs 1.5% with placebo
    •   23% of patients achieved SALT ≤20with LITFULO 50 mg vs 1.6% with placebo
Patient images demonstrate examples of three patients from the ALLEGRO trial.[2,4]
Individual results may vary.
Picture 60.8 -> 0.48 from ref. 2 figure 3F.                Picture 61.2 -> 13.6 and 54.9 -> 1.7 from ref. 4 figure S8

Patient images are used with permission.

 Explore safety data Safety Loading
SALT=Severity of Alopecia Tool.
References:1. LITFULO (ritlecitinib) SmPC. 2.King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. Data on file. Pfizer Inc; New York, NY. 4.King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2  

    tab 6

     Indication Litfulo® (ritlecitinib):
     Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.    [Litfulo SmPC] 
     Litfulo pligttekst
    Explore safety data Safety Loading
    Get appropriate patients started on LITFULO today Getting started Loading

    Bivirkninger skal indberettes. Hvis du vil rapportere en bivirkning, kan du kontakte Pfizer på e-mail: [email protected]

     

    PfizerPro kontoPfizerPro konto

    Få adgang til information, materialer, efteruddannelse samt modtag kommunikation om Pfizers lægemidler og vacciner.

    Log indRegisterMin profilLog ud

    Informationen på dette website er kun beregnet til Sundhedspersoner i Danmark.

    Denne hjemmeside er udarbejdet til dig af Pfizer Danmark.

     

    © Pfizer 2023. Alle rettigheder til denne hjemmeside forbeholdes Pfizer ApS.

    12 August 2025 * PP-LGF-DNK-0008
    Du forlader nu Pfizer
    Du forlader nu et Pfizer-drevet website. Links til alle eksterne websites leveres som en ressource til vores besøgende. Pfizer påtager sig intet ansvar for indholdet af websites, der ikke ejes og drives af Pfizer.